Hikma announces FDA approval and launch of Fluticasone 50 MCG Spray, the store brand equivalent of Flonase®
5/31/2016 12:00:00 AM
WestWardProduct
News Icon Image

Hikma announces FDA approval and launch of Fluticasone 50 MCG Spray, the store brand equivalent of Flonase®


London, 31 May 2016 – Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody’s / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, today announces the approval of Fluticasone 50 MCG Spray, the store brand equivalent of Flonase®, by the U.S. Food and Drug Administration (FDA).

Flonase® (fluticasone propionate nasal spray USP, 50 mcg per spray) is indicated for the temporary relief of hay fever or other upper respiratory allergies in adult and paediatric patients 4 years of age and older. Combined generic and branded sales for the twelve months ending May 2016 were $343 million.

Hikma, through its wholly-owned subsidiary West-Ward Pharmaceuticals, has partnered with Perrigo Company plc, a leading supplier of over-the-counter (OTC) products, for the launch of this product in the OTC market.  Perrigo expects to begin customer shipments immediately. 

Michael Raya, Chief Executive of West-Ward Pharmaceuticals, said:
“We are very pleased to be working with Perrigo to improve access to this important product for consumers interested in purchasing fluticasone propionate nasal spray over-the-counter.”

Click to read this Press Release on Hikma.com.

-- ENDS --

Enquiries

Hikma Pharmaceuticals PLC
Susan Ringdal, VP Corporate Strategy and Investor Relations +44 (0)20 7399 2760

West-Ward Pharmaceuticals

Keri Butler, Public Affairs & Communications +1 614 272 4774
FTI Consulting
Ben Atwell/ Matthew Cole / Julia Phillips +44 (0)20 3727 1000

About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: “Injectables”, “Branded” and “Generics”, based principally in the United States, the Middle East and North Africa (MENA) and Europe. Hikma currently employs over 7,000 staff members worldwide.

About West-Ward Pharmaceuticals 
West-Ward Pharmaceuticals, a wholly-owned subsidiary of Hikma Pharmaceuticals PLC, is a top ten generic pharmaceutical company in the US focused on providing a broad range of differentiated generic pharmaceutical products across a range of dosage forms. West-Ward has sites in New Jersey, Ohio and Tennessee.

About Perrigo
Perrigo Company plc, a top five global over-the-counter ("OTC") consumer goods and pharmaceutical company, offers patients and customers high quality products at affordable prices. From its beginnings in 1887 as a packager of generic home remedies, Perrigo, headquartered in Ireland, has grown to become the world's largest manufacturer of OTC products and supplier of infant formulas for the store brand market. The Company is also a leading provider of generic extended topical prescription products and receives royalties from Multiple Sclerosis drug Tysabri®. Perrigo provides Quality Affordable Healthcare Products® across a wide variety of product categories and geographies primarily in North America, Europe, and Australia, as well as other markets, including Israel, China and Latin America. Visit Perrigo online at (http://www.perrigo.com).

 

  • WW_LOGO
  • West-Ward Pharmaceuticals Corp.

    401 Industrial Way West

    Eatontown, New Jersey 07724-2206

  • Hikma Logo
  • West-Ward Pharmaceuticals Corp. is a subsidiary of Hikma Pharmaceuticals PLC

  • VAWD Logo
  • 2009-Current West-Ward Pharmaceuticals Corp. Memphis’ distribution center is the first distribution center to be awarded “Verified-Accredited Wholesale Distributors® (VAWD®) accreditation” by The National Association of Boards of Pharmacy® (NABP®).

    Click Here for more information